Alphyn Biologics Presents New Data from Phase 2a Trial Showing Significant Improvement of Mild-to-Moderate Atopic Dermatitis
(Adnkronos) – – Statistically significant improvements in IGA (Investigator Global Assessment) and EASI (Eczema Area and Severity Index) scores – Fast itch reduction by day 4 and sustained itch reduction – Body
